AntiDFS70 Lupus Nephritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-15

Study Completion Date

2024-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Systemic lupus erythematous (SLE) is a heterogeneous autoimmune disease that involve many different organs and display a variable clinical course. The prevalence of SLE varies across gender, race/ethnicity, and geographic regions. SLE demonstrates a striking female predominance with a peak incidence of disease during the Reproductive years. In adults, the female to male ratio is 10- 15:1(1)( 2)

Clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe, life-threatening internal organ disease. Constitutional symptoms, rash, mucosal ulcers, inflammatory polyarthritis, photosensitivity, and serositis are the most common clinical features of the disease. (3) (4) Anti-DFS70 antibodie) and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies , there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of antinuclear antibodies associated rheumatic diseases. (8)

Anti-DFS70 antibodies were not associated with lupus nephritis development in Systemic lupus erythematosus patients but were associated with anti-dsDNA antibodies , proliferative lupus nephritis, and renal activity index . This suggests their potential to serve as a non-histological biomarker for lupus nephritis subclass and activity status. (8)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients

NCT05964751

Lupus Nephritis

UNKNOWN

Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

NCT07017868

Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

RECRUITING

Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus

NCT05900232

Systemic Lupus Erythematosus

UNKNOWN NA

Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital

NCT04756492

We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital

UNKNOWN

Serum Levels of Angiotensin Converting Enzyme in Systemic Lupus Erythematous Patients

NCT05516511

Systemic Lupus Erythematosus

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group A

systemic lupus erythematosus cases, diagnosed by SLICC criteria with negative levels of AntiDFS antibodies

anti dfs70 antibodies

Intervention Type DIAGNOSTIC_TEST

blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre

group B

systemic lupus erythematosus cases, diagnosed by SLICC criteria with positive levels of AntiDFS antibodies

anti dfs70 antibodies

Intervention Type DIAGNOSTIC_TEST

blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anti dfs70 antibodies

blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who fulfill the 2019 American College of Rheumatology/European League against Rheumatism classification criteria of Systemic Lupus Erythematous . (9)
2. Patients who is able to give informed consent to join the study.

•